<DOC>
	<DOCNO>NCT02451150</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics safety single dose TAK-536 ( azilsartan ) pediatric patient age 6 less 16 year hypertension .</brief_summary>
	<brief_title>A Phase 3 Pharmacokinetic Study TAK-536 ( Azilsartan ) Pediatric Patients 6 Less Than 16 Years With Hypertension</brief_title>
	<detailed_description>The drug test study call azilsartan . Azilsartan test evaluate process body ( pharmacokinetics ) . This study look lab result pediatric participant take azilsartan . The study enrol 6 patient . Participants assign study medication dose body weight follow : - Body Weight &lt; 50 kg : azilsartan 5 mg - Body Weight ≥50 kg : azilsartan 10 mg All participant take single oral dose azilsartan Day 1 study . This multi-center trial conduct Japan . The overall time participate study 17 day . Participants make multiple visit clinic , contact telephone Day 6 Day 15 last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . In opinion investigator subinvestigator , participant 's parent legal guardian capable understand comply study requirement . 2 . The participant 's parent legal guardian capable sign date write informed consent form behalf participant prior initiation study procedure . Written inform assent also obtain participant much possible . 3 . The participant diagnose hypertensive ( participant receive antihypertensive therapy , diagnosis base Age GenderBased Blood Pressure Reference Children . Sitting diastolic blood pressure [ DBP ] systolic blood pressure [ SBP ] least 95th percentile essential hypertension present without concurrent hypertensive organ damage least 90th percentile secondary hypertension present concurrent chronic renal disease , diabetes mellitus , heart failure , hypertensive organ damage ) . 4 . The participant male female age 6 less 16 year time consent . 5 . The participant weighs least 20 kg observation period . 6 . The participant capable take tablet provide study drug . 7 . Participants renal transplant meet following condition : At least 6 month elapse transplant start observation period stable graft function 6 month ( estimate glomerular filtration rate [ eGFR ] ≥ 30 mL/min/1.73 m^2 ) historical documentation ( Doppler echo compute tomography [ CT ] , magnetic resonance image [ MRI ] , etc . ) verify arterial stenosis present transplant kidney . For participant receive immunosuppressive therapy , dose stable least 30 day study drug administration . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing informed consent within 1 month completion study negative pregnancy test result observation period . 1 . The participant receive investigational drug within 30 day prior start observation period currently participate another clinical study postmarketing study . Note : This apply participants participate observational study without interventional invasive therapy . 2 . The participant determine poorly control hypertension ( general guideline , clinical sit blood pressure measure , SBP least 15 mmHg high and/or DBP least 10 mmHg high 99th percentile Age GenderBased Blood Pressure Reference Children ) . 3 . The participant diagnose malignant hypertension rapidly progressive hypertension . 4 . The participant severe renal dysfunction ( eGFR &lt; 30 mL/min/1.73 m^2 ) , dialysis treatment , renovascular disease affect kidney solitary kidney , severe nephrotic syndrome remission , serum albumin &lt; 2.5 g/dL . 5 . The participant history clinical manifestation serious cardiovascular , hepatobiliary , gastrointestinal , endocrine ( e.g. , hyperthyroidism Cushing 's syndrome ) , hematologic , immunologic , genitourinary , psychiatric disease ; cancer ; and/or condition would interfere health status participant study participation would jeopardize study integrity opinion investigator subinvestigator . 6 . The participant leave ventricular outflow tract obstruction affect hemodynamics due aortic stenosis , aortic valve disease , like schedule surgery affect blood pressure ( e.g. , repair arterial anomaly ) study . 7 . The participant underwent surgical procedure major bleed within 6 month start observation period . 8 . The participant past present clinically significant abnormality 12lead electrocardiogram ineligible study opinion investigator subinvestigator . 9 . The participant poorly control diabetes mellitus ( hemoglobin A1c [ HbA1c ] &gt; 9.0 % observation period ) 10 . The participant either alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] least 2.5 time upper limit standard value total bilirubin least 1.5 time upper limit standard value , severe hepatic dysfunction , active liver disease ( regardless etiology ) , jaundice observation period . 11 . The participant hyperkalemia exceed upper limit standard value observation period . 12 . The participant history hepatitis B , hepatitis C , human immunodeficiency virus infection start observation period . 13 . The participant history hypersensitivity allergy angiotensin II receptor blocker ( ARBs ) . 14 . The participant require treatment prohibited concomitant drug ( ) . 15 . Peripheral venous blood collection participant difficult . 16 . The participant clinically significant acute disease within 30 day day study drug administration . 17 . If female , participant pregnant lactating , intend become pregnant give consent , study period , within 1 month study completion .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>